Objectives: Melanoma is a type of skin cancer derived from melanocytes, with a high mortality rate and a poor prognosis. Interestingly, it has been demonstrated that melanoma patients present a spontaneous T-cell response against their tumor, but at a certain time, the immune response becomes ineffective. In this process, T cells are suppressed, favoring tumor escape and growth. In order to investigate whether the immune system itself could favor tumor evasion, we explored the potential of the secretome generated by melanoma to control T cell functions, considering the exposure of tumor cells to an inflammatory or non-inflammatory environment. Materials and methods: Initially, PBMCs were isolated from healthy donors (n = 4) and cultured for...
Objective: The immune system can halt cancer progression by suppressing outgrowth of clinically occu...
In the absence of a local inflammatory response, expression of MHC class II molecules is restricted ...
Background Immunotherapy with checkpoint inhibitors has shown impressive results in patients with me...
The development of immunotherapeutic approaches for the treatment of melanoma requires a better unde...
Item does not contain fulltextMelanoma is a highly heterogeneous tumor for which recent evidence sup...
Completed under a Cotutelle arrangement between the University of Melbourne and University of Bonn©...
While the immune system can control tumour growth, regulatory mechanisms, necessary in preventing im...
Melanoma is an immunogenic tumor whose relationship with immune cells resident in the microenvironme...
© 2018 Dr. Simone Louise ParkIn addition to its role in protecting the body from infection, the immu...
Cutaneous melanoma is the most common skin cancer with an incidence that has been rapidly increasing...
Melanoma is one of the most immunogenic tumors and its relationship with host immune system is curre...
Treatment of metastatic melanoma with tumor reactive T cells (adoptive T cell therapy, ACT) is a pro...
Background: Melanoma the most immunogenic cancer type and metastatic melanoma has poor prognosis. Cu...
International audience: BackgroundIt is well established that inflammation promotes cancer, includin...
While T cell-based immunotherapies are steadily improving, there are still many patients who progres...
Objective: The immune system can halt cancer progression by suppressing outgrowth of clinically occu...
In the absence of a local inflammatory response, expression of MHC class II molecules is restricted ...
Background Immunotherapy with checkpoint inhibitors has shown impressive results in patients with me...
The development of immunotherapeutic approaches for the treatment of melanoma requires a better unde...
Item does not contain fulltextMelanoma is a highly heterogeneous tumor for which recent evidence sup...
Completed under a Cotutelle arrangement between the University of Melbourne and University of Bonn©...
While the immune system can control tumour growth, regulatory mechanisms, necessary in preventing im...
Melanoma is an immunogenic tumor whose relationship with immune cells resident in the microenvironme...
© 2018 Dr. Simone Louise ParkIn addition to its role in protecting the body from infection, the immu...
Cutaneous melanoma is the most common skin cancer with an incidence that has been rapidly increasing...
Melanoma is one of the most immunogenic tumors and its relationship with host immune system is curre...
Treatment of metastatic melanoma with tumor reactive T cells (adoptive T cell therapy, ACT) is a pro...
Background: Melanoma the most immunogenic cancer type and metastatic melanoma has poor prognosis. Cu...
International audience: BackgroundIt is well established that inflammation promotes cancer, includin...
While T cell-based immunotherapies are steadily improving, there are still many patients who progres...
Objective: The immune system can halt cancer progression by suppressing outgrowth of clinically occu...
In the absence of a local inflammatory response, expression of MHC class II molecules is restricted ...
Background Immunotherapy with checkpoint inhibitors has shown impressive results in patients with me...